Info

Acologix is focused on the identification, development and commercialization of innovative medicines that offer new solutions to the clinical problems in the osteo-renal field that are not adequately addressed by existing therapies. Moreover, by focusing on novel mechanisms of action to treat unmet medical needs, Acologix believes that its product candidates will have distinct advantages over existing therapies and open opportunities for new markets. Another proven strength of Acologix is its business development capability to identify and in-license unique and patent-protected therapeutic candidates that have a large market potential. It is supported by the Company's profound knowledge about the market and unmet medical needs in its target areas. The Company's most advanced product candidate is TRK-820 for uremic pruritus, a severe systemic itch in kidney dialysis patients. Acologix is currently planning a Phase III study with TRK-820 in hemodialysis subjects with uremic pruritus in the United States for 2008. Acologix' partner, Toray has successfully completed a phase III trial in hemodialysis patients with uremic pruritus in Japan and has filed for approval in Japan. Acologix licensed TRK-820 from Toray Industries, Inc. in June 2005. Acologix has completed two Phase II studies evaluating AC-100, or Dentonin®-one for tooth restoration and the other for oral bone regeneration. AC-100 is currently being evaluated for orthopedic applications. Acologix is investigating AC-200, or Phosphatonin, a human endogenous hormone, in preclinical studies for the treatment of hyperphosphatemia, an elevated level of phosphate in the blood, which commonly occurs in patients with advanced renal failure.